Learn More
BACKGROUND Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. METHODS In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15(More)
OBJECTIVE In spite of the recent interest in endoscopic third ventriculostomy, ventriculoperitoneal (VP) shunt is still the gold standard in treating non-obstructive hydrocephalus in children. The peritoneal cavity remains the optimal site for cerebrospinal fluid (CSF) diversion. Shunt insertion and re-interventions carry a high risk of inaesthetic(More)
Synthetic TRH and PL were administered orally for 3 weeks (300 mg./day), to long-term institutionalized chronic schizophrenic patients, within the framework of a double blind placebo controlled crossover study. Significant changes in physiological and laboratory parameters suggested increased thyroid activity, but significant favorable psychiatric and(More)
  • 1